A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging - Abstract

College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA.


The purpose of this study was to evaluate the tumor targeting and imaging properties of a novel (111)In-labeled gonadotropin-releasing hormone (GnRH) peptide {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Ahx-(d-Lys(6)-GnRH1)} for human prostate cancer. The biodistribution and tumor imaging properties of (111)In-DOTA-Ahx-(d-Lys(6)-GnRH1) were determined in DU145 human prostate cancer-xenografted nude mice. (111)In-DOTA-Ahx-(d-Lys(6)-GnRH1) exhibited rapid tumor uptake (1.27±0.40% ID/g at 0.5h post-injection) coupled with fast whole-body clearance through the urinary system. The DU145 human prostate cancer-xenografted tumor lesions were clearly visualized by single photon emission computed tomography (SPECT)/CT at 0.5h post-injection of (111)In-DOTA-Ahx-(d-Lys(6)-GnRH1). The successful imaging of DU145 human prostate cancer-xenografted tumor lesions using (111)In-DOTA-Ahx-(d-Lys(6)-GnRH1) highlighted its potential as a novel imaging probe for human prostate cancer imaging.

Written by:
Guo H, Gallazzi F, Sklar LA, Miao Y.   Are you the author?

Reference: Bioorg Med Chem Lett. 2011 Sep 15;21(18):5184-7.
doi: 10.1016/j.bmcl.2011.07.055

PubMed Abstract
PMID: 21821417

UroToday.com Prostate Cancer Section